-
Article
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease
With the implementation of the 11th edition of the International Classification of Diseases (ICD-11) and the publication of the metabolic dysfunction-associated fatty liver disease (MAFLD) nomenclature in 2020...
-
Article
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
In the past 3 decades, metabolic-associated fatty liver disease (MAFLD) has emerged as a widespread liver condition, with its global prevalence on the rise. It ranks as a leading contributor to hepatocellular ...
-
Article
Prevalence and incidence of MAFLD and associated anthropometric parameters among prepubertal children of the Shanghai Birth Cohort
Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common chronic liver disease in adolescent and adult population. However, the epidemiologic data of MAFLD in prepubertal children remain...
-
Article
Open AccessGenetically predicted plasma levels of amino acids and metabolic dysfunction-associated fatty liver disease risk: a Mendelian randomization study
Emerging metabolomics-based studies suggested links between amino acid metabolism and metabolic dysfunction-associated fatty liver disease (MAFLD) risk; however, whether there exists an aetiological role of am...
-
Article
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Fatty liver disease in the absence of excessive alcohol consumption is an increasingly common condition with a global prevalence of ~ 25–30% and is also associated with cardiovascular disease (CVD). Since syst...
-
Article
Open AccessProlyl endopeptidase remodels macrophage function as a novel transcriptional coregulator and inhibits fibrosis
Macrophages are immune cells crucial for host defense and homeostasis maintenance, and their dysregulation is involved in multiple pathological conditions, such as liver fibrosis. The transcriptional regulatio...
-
Article
Open AccessFurthering research on MAFLD: the APASL Metabolic fAtty lIver DiseasE coNsortium (MAIDEN)
-
Article
Reliability and validity of the Chinese version of chronic liver disease questionnaire-nonalcoholic fatty liver disease in patients with nonalcoholic fatty liver disease: a multicenter cross-sectional survey in China
The Chronic Liver Disease Questionnaire (CLDQ)-Nonalcoholic Fatty Liver Disease (NAFLD) is a disease-specific instrument to assess the health-related quality of life (HRQL) of patients with NAFLD. In order to ...
-
Article
Open AccessThe hepato-ovarian axis: genetic evidence for a causal association between non-alcoholic fatty liver disease and polycystic ovary syndrome
Recent studies found associations between non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS), but the causal nature of this association is still uncertain.
-
Article
Open AccessGenome-wide placental DNA methylations in fetal overgrowth and associations with leptin, adiponectin and fetal growth factors
Fetal overgrowth “programs” an elevated risk of type 2 diabetes in adulthood. Epigenetic alterations may be a mechanism in programming the vulnerability. We sought to characterize genome-wide alterations in pl...
-
Article
MAFLD, patient-centred care, and APASL
Asian–Pacific nations are home to more than half the world’s population and similar to other global super regions, metabolic dysfunction associated fatty liver disease (MAFLD) is the principal cause for chroni...
-
Article
Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis
Currently, nonalcoholic steatohepatitis (NASH) is one of the most common forms of chronic hepatitis, increasing the burden of health care worldwide. In patients with NASH, the fibrosis stage is the most predic...
-
Article
Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis
Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease that is increasingly prevalent worldwide. Liver inflammation is an important contributor to disease progression from nonalcoholic fatty liv...
-
Article
Open AccessHealth-related quality of life in Chinese population with non-alcoholic fatty liver disease: a national multicenter survey
Health Related Quality of Life (HRQL) is a multi-dimensional construct that can comprehensively evaluate the patient’s health status, including physical, emotional, mental and social well-being. In this study,...
-
Article
What are the clinical settings and outcomes of lean NAFLD?
The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased rapidly and is associated with obesity in epidemiology and pathogenesis. A new study reports that hepatic and extrahepatic complications...
-
Article
Open AccessThe gut mycobiome: a novel player in chronic liver diseases
The human gut microbiome (bacteria, fungi, viruses, and archaea) is a complex and diverse ecosystem. It plays an important role in human health, but is involved in several intestinal and extraintestinal diseas...
-
Article
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease
Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver disease and affects nearly a quarter of the global population. The objective of this work was to present the clinical ...
-
Article
Open AccessPredictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study
The Gut and Obesity in Asia (GOASIA) Workgroup was formed to study obesity and gastrointestinal diseases in the Asia Pacific region. We aimed to 1) compare the characteristics of elderly (i.e. age ≥ 60) vs. no...
-
Article
Open AccessTherapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis
Ceramide plays pathogenic roles in nonalcoholic fatty liver disease (NAFLD) via multiple mechanisms, and as such inhibition of ceramide de novo synthesis in the liver may be of therapeutically beneficial in pa...
-
Article
Open AccessIndole-3-propionic acid inhibits gut dysbiosis and endotoxin leakage to attenuate steatohepatitis in rats
Microbial metabolites have emerged as critical components that mediate the metabolic effects of the gut microbiota. Here, we show that indole-3-propionic acid (IPA), a tryptophan metabolite produced by gut bac...
